Full-Time

Vice President of Clinical Operations

Remote

Updated on 11/15/2024

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Senior

New York, NY, USA

Office located at 151 West 42nd Street, 15th Floor, New York, NY 10036.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor's Degree in a scientific discipline; advanced degree preferred
  • 15+ years of clinical operations management experience, including trial leadership experience
  • Experience managing CROs and key clinical vendors required
  • Experience developing clinical study protocols in conjunction with a study team required
  • Track record leading clinical operations teams to deliver on time execution and results, including outsourced support
  • Early and late phase investigational product development experience required
  • Demonstrated ability to set and prioritize goals and objectives; excellent time management, negotiation, problem-solving and organizational skills
  • Proven excellence in clinical operations strategy including simultaneous oversight of multiple trials, and ideally experience managing multiple vendors in dispersed project team environments
  • Experience in building infrastructure (including SOPs) required
  • Ability to work independently and collaboratively in a fast-paced, matrixed team environment consisting of internal and external team members
  • Entrepreneurial mindset, bringing in creative ideas to challenge the status quo of clinical trial execution
  • Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines
  • Excellent understanding and demonstrated application of FDA guidelines, Good Clinical Practices and applicable Standard Operating Procedures
  • Strong leadership skills with ability to innovate and collaborate with a small team to articulate clear clinical strategy
  • Strong communication and presentation skills
Responsibilities
  • Leadership responsibility for Clinical Operations strategy, initiation and execution of clinical trials across all phases, including (but not limited to) CRO/vendor selection, site engagement, contracts & budgets, CRO oversight, and proactive risk management to ensure the quality conduct of trials with a high level of data integrity
  • Provide excellent direct line management and training/mentoring of Clinical Operations team members, creating a nimble, versatile, world-class, high performing operations team
  • Scoping geographic region and site specific approaches with substantial experience in global clinical trial execution for successful incubation of trials during diligence and launch post transaction is highly critical
  • Demonstrate leadership in preemptively identify and develop outlines of indication- and phase-specific operations plan before and during diligence to arrive at the most realistic estimates of enrolment and data availability timelines in the integrated development plan underwritten in the Investment Thesis
  • Work cross functionally to drive the strategy and own implementation for clinical programs and manage the integrated development plans to deliver against company goals
  • Lead and supervise all aspects of study progress from concept to close-out to assure adherence to Good Clinical Practice, intended timelines and achievement of study goals while ensuring quality in accordance with regulatory guidelines;
  • Serve as Clinical Operations point of contact for strategic governance bodies (e.g., Safety Team, Project Team), as well as portfolio planning and business development opportunities
  • Lead Clinical Study teams in gathering and reporting key study data collection and presentation to use in support of regulatory filings, as well as project team and management communications
  • Oversee identification, qualification and selection of CROs and vendors needed to conduct clinical trials including approval of Master Services Agreements and Task Orders with CRO
  • Establish governance procedures for CROs and key clinical vendors ensuring continuous performance oversight and process improvement
  • Liaise with KOLs, Investigators, and clinical site staff to ensure optimal Sponsor-Site relationships
  • Liaise effectively with vant staff, including management and execution team
  • Provide scientific/clinical expertise in the design and interpretation of clinical studies
  • Build and implement repeatable and scalable approaches to enrollment projections, geostrategy and patient enrollment essential for future vant planning and execution
  • Implement novel technologies, platforms, tools to improve and scale core capabilities such as enrollment projections, geostrategy and patient enrollment essential for future vant planning and execution
  • Ensure effective project or program communications and updates to internal and external stakeholders through meetings, presentations, and other methods

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.

Help us improve and share your feedback! Did you find this helpful?